Cabergoline (a long-acting D2R agonist, see Table 3) administration, at the dose of 10 μg/kg via i.g., had no influence on clinical and macroscopic signs of IA-induced colitis in the rats or in vascular permeability. The gene discussed is DRD2; the disease is colitis.